Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

BPC-157TB-500Thymosin β4 (full)GHK-Cu

Dimension	BPC-157 Body Protection Compound 157	TB-500 Thymosin Beta-4 fragment	Thymosin β4 (full) TB4	GHK-Cu Copper Tripeptide-1
Evidence tier	CPreclinical only	CPreclinical only	BHuman observational	BHuman observational
Intelligence Score™	4.1/ 10 · Emerging	3.9/ 10 · Emerging	5.3/ 10 · Emerging	5.2/ 10 · Emerging
Family	Gastric pentadecapeptide	Actin-sequestering peptide	Actin-sequestering peptide	Copper-binding tripeptide
Half-life	~30 min (subcutaneous, rodent)	~2–3 h	~2 h	Short (minutes, plasma)
Typical dose	200–500 mcg/day	2–5 mg/week, divided	Investigational	1–2 mg/day (anecdotal, injectable)
Routes	Subcutaneous, Oral (stable form)	Subcutaneous, Intramuscular	Subcutaneous, Ophthalmic	Topical, Subcutaneous
Tier label	Preclinical only	Preclinical only	Human observational	Human observational
Mechanism	Modulates nitric oxide system, upregulates GH receptor; promotes angiogenesis preclinically.	Binds G-actin; regulates cytoskeletal organisation; endothelial migration preclinically.	G-actin sequestering; modulates inflammation and angiogenesis.	Modulates wound-healing gene expression; binds copper(II) with high affinity.
Reported uses	tendon-injury, joint-pain	tendon-injury	tendon-injury	recovery-sleep
Contraindications	— Active malignancy (theoretical) — Pregnancy — no human data	— Active malignancy (theoretical) — Pregnancy	— Pregnancy	— Wilson's disease — Copper sensitivity
Citations	1	1	1	1

CPreclinical only

Intelligence Score™: 4.1/ 10 · Emerging
Family: Gastric pentadecapeptide
Half-life: ~30 min (subcutaneous, rodent)
Typical dose: 200–500 mcg/day
Routes: Subcutaneous, Oral (stable form)
Tier label: Preclinical only
Mechanism: Modulates nitric oxide system, upregulates GH receptor; promotes angiogenesis preclinically.
Reported uses: tendon-injury, joint-pain
Contraindications: — Active malignancy (theoretical)
— Pregnancy — no human data
Citations: 1

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: Actin-sequestering peptide
Half-life: ~2–3 h
Typical dose: 2–5 mg/week, divided
Routes: Subcutaneous, Intramuscular
Tier label: Preclinical only
Mechanism: Binds G-actin; regulates cytoskeletal organisation; endothelial migration preclinically.
Reported uses: tendon-injury
Contraindications: — Active malignancy (theoretical)
— Pregnancy
Citations: 1

BHuman observational

BHuman observational

Intelligence Score™: 5.2/ 10 · Emerging
Family: Copper-binding tripeptide
Half-life: Short (minutes, plasma)
Typical dose: 1–2 mg/day (anecdotal, injectable)
Routes: Topical, Subcutaneous
Tier label: Human observational
Mechanism: Modulates wound-healing gene expression; binds copper(II) with high affinity.
Reported uses: recovery-sleep
Contraindications: — Wilson's disease
— Copper sensitivity
Citations: 1

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.